Prostate cancer has become, in the last decades, the most frequently diagnosed cancer in the male population of Western countries; the data collected by the Italian Cancer Registers confirm this evidence also for 2020 (over 36,000 new diagnoses, representing 19% of all male cancers). Mortality rates are, on the other hand, decreasing: net survival 5 years after diagnosis reaches 92%.1 The increasing number of men with prostate cancer diagnoses and the rising life expectancies highlight the importance of evaluating the quality of life (QoL) among these patients. Several studies reported very interesting results about QoL of PCa patients,2–4 but the generalizability of these results may be limited across different populations, due to differences in measurement tools and reporting methods. Nonetheless, understanding the efficacy and harms of each treatment is important in patients’ counseling and shared decision-making process. Therefore, the “PROState cancer monitoring in Italy” project from the National Research Council (Pros-IT CNR) was designed, with the main aim to monitor QoL in PCa patients.5 Briefly, it is a longitudinal and observational study, involving 97 Urology, Radiation Oncology and Medical Oncology facilities located throughout Italy, enrolling a non-probability convenience sample of 1705 treatment-naïve patients with histologically confirmed PCa from September 2014 to September 2015. Patients were enrolled at PCa diagnosis (baseline) and were followed at 6 time-points after diagnosis (from 6 to 60 months from the diagnosis), evaluating treatments performed and QoL through the Short-Form Health Survey (SF-126) and the University of California Los Angeles-Prostate Cancer Index (Italian UCLA-PCI7,8).